Key Dates

Related Announcements

•  November 8, 2023 - Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional). See NOFO PAR-24-062     
• October 5, 2023 - Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required).  See NOFO RFA-DA-25-019
• October 5, 2023 - Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional).  See NOFO RFA-DA-25-059
• September 11, 2023 - Intervention Research to Improve Native American Health (R34 Clinical Trial Optional).  See NOFO PAR-23-285
• October 4, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional).  See NOFO RFA-DA-23-062
• August 9, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional).  See NOFO RFA-DA-23-061
• May 9, 2022 - Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional).  See NOFO PAR-22-182
• May 9, 2022 - Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional).  See NOFO PAR-22-183
• September 8, 2021 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional).  See NOFO RFA-DA-22-040
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

Purpose:

This Notice of Special Interest (NOSI)  calls for research to build a body of evidence on how to implement and  sustain overdose education and naloxone distribution (OEND)  in HIV prevention and care settings. 

Background:

In the United States, people living with HIV (PLWH) are at a higher risk of dying from a drug overdose than from HIV/AIDS-related complications. Overdose is also the leading cause of death among PLWH who inject drugs. HIV care settings provide  an opportunity to offer all individuals using or at risk of using illicit substances  OEND . Increased screening for substance use and overdose risk, with the provision of OEND (e.g., education and training regarding overdose prevention, overdose recognition and rescue response, and issuing naloxone kits) in HIV care settings could provide an opportunity to save lives of PLWH by reducing the risk of fatal overdose. 

Research opportunities and Scope: 

HIV prevention settings provide an additional venue for OEND. These venues  can include settings that routinely provide HIV testing, pre-exposure prophylaxis (PrEP) clinics, and providers whose practices include large numbers of people at risk for HIV acquisition, particularly people who use substances. Emergency departments and other settings that routinely see people who use substances but are not always able to determine HIV status may also be effective venues for this work. Harm reduction settings vary in their implementation of OEND; efforts to more consistently offer OEND in harm reduction settings is also important. 

This NOSI calls for research to build a body of evidence  on how to implement and  sustain  OEND in HIV prevention and care settings. Research should develop and test models for integrating OEND; examine barriers and facilitators to successful implementation; and develop implementation strategies to address provider, organizational, structural, reimbursement and other factors impacting implementation. In addition, applications should  describe how OEND efforts will be sustained beyond the conclusion of the research. Outcomes from the research studies should include  implementation strategies and models generalizable to other HIV prevention and care settings. Key elements that must be considered in all applications include: 

• Health disparities and inequities and the relevance to the interventions or services being studied; 
• Meaningful engagement of relevant providers and community partners in study conceptualization, design, execution, and interpretation; 
• Perspectives of end users of the services or interventions;  
• Sustainability of the proposed intervention should it prove to be successful;
• Potential scalability of the proposed intervention.

 Application and Submission Information:

This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through May 08, 2027. 

Submit applications for this initiative using one of the following Notices of Funding Opportunity (NOFOs) or any reissuances of these announcements through the expiration date of this notice."

•  November 8, 2023 - Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional). See NOFO PAR-24-062     
• October 5, 2023 - Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required).  See NOFO RFA-DA-25-019
• October 5, 2023 - Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional).  See NOFO RFA-DA-25-059
• September 11, 2023 - Intervention Research to Improve Native American Health (R34 Clinical Trial Optional).  See NOFO PAR-23-285
• October 4, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional).  See NOFO RFA-DA-23-062
• August 9, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional).  See NOFO RFA-DA-23-061
• May 9, 2022 - Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional).  See NOFO PAR-22-182
• May 9, 2022 - Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional).  See NOFO PAR-22-183
• September 8, 2021 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional).  See NOFO RFA-DA-22-040
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185

All instructions in the SF424 (R&R) Application Guide  and the NOFO used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-DA-25-031” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.

Scientific/Research Contact(s)

Redonna Chandler, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1919
Email: redonna.chandler@nida.nih.gov

Angela Lee-Winn, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-451-7206
Email: angela.lee-winn@nih.gov